These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 26603680)

  • 21. Serelaxin: a novel therapy for acute heart failure with a range of hemodynamic and non-hemodynamic actions.
    Díez J
    Am J Cardiovasc Drugs; 2014 Aug; 14(4):275-85. PubMed ID: 24590581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial.
    Filippatos G; Teerlink JR; Farmakis D; Cotter G; Davison BA; Felker GM; Greenberg BH; Hua T; Ponikowski P; Severin T; Unemori E; Voors AA; Metra M
    Eur Heart J; 2014 Apr; 35(16):1041-50. PubMed ID: 24316514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study.
    Cotter G; Voors AA; Prescott MF; Felker GM; Filippatos G; Greenberg BH; Pang PS; Ponikowski P; Milo O; Hua TA; Qian M; Severin TM; Teerlink JR; Metra M; Davison BA
    Eur J Heart Fail; 2015 Nov; 17(11):1133-43. PubMed ID: 26333529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection.
    Díez J; Ruilope LM
    Eur Heart J Cardiovasc Pharmacother; 2016 Apr; 2(2):119-30. PubMed ID: 27418970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes: An Exploratory Analysis From the RELAX-AHF Trial.
    Pang PS; Teerlink JR; Voors AA; Ponikowski P; Greenberg BH; Filippatos G; Felker GM; Davison BA; Cotter G; Kriger J; Prescott MF; Hua TA; Severin T; Metra M
    JACC Heart Fail; 2016 Jul; 4(7):591-599. PubMed ID: 27039129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure.
    Ponikowski P; Mitrovic V; Ruda M; Fernandez A; Voors AA; Vishnevsky A; Cotter G; Milo O; Laessing U; Zhang Y; Dahlke M; Zymlinski R; Metra M
    Eur Heart J; 2014 Feb; 35(7):431-41. PubMed ID: 24255129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cause of Death in Patients With Acute Heart Failure: Insights From RELAX-AHF-2.
    Loungani RS; Teerlink JR; Metra M; Allen LA; Butler J; Carson PE; Chen CW; Cotter G; Davison BA; Eapen ZJ; Filippatos GS; Gimpelewicz C; Greenberg B; Holbro T; Januzzi JL; Lanfear DE; Pang PS; Piña IL; Ponikowski P; Miller AB; Voors AA; Felker GM
    JACC Heart Fail; 2020 Dec; 8(12):999-1008. PubMed ID: 33189635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis.
    Teerlink JR; Davison BA; Cotter G; Maggioni AP; Sato N; Chioncel O; Ertl G; Felker GM; Filippatos G; Greenberg BH; Pang PS; Ponikowski P; Edwards C; Senger S; Teichman SL; Nielsen OW; Voors AA; Metra M
    Eur J Heart Fail; 2020 Feb; 22(2):315-329. PubMed ID: 31886953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serelaxin for the treatment of heart failure.
    Moin DS; Bloom MW; Papadimitriou L; Butler J
    Expert Rev Cardiovasc Ther; 2016 Jun; 14(6):667-75. PubMed ID: 27045761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial.
    Filippatos G; Farmakis D; Metra M; Cotter G; Davison BA; Felker GM; Greenberg BH; Hua TA; Pang PS; Ponikowski P; Qian M; Severin TA; Voors AA; Teerlink JR
    Clin Res Cardiol; 2017 Jun; 106(6):444-456. PubMed ID: 28150186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relaxin: a novel agent for the treatment of acute heart failure.
    Wilson SS; Ayaz SI; Levy PD
    Pharmacotherapy; 2015 Mar; 35(3):315-27. PubMed ID: 25759289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging role of serelaxin in the therapeutic armamentarium for heart failure.
    Varr BC; Maurer MS
    Curr Atheroscler Rep; 2014 Oct; 16(10):447. PubMed ID: 25108571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The RELAX-AHF study].
    Mortara A
    G Ital Cardiol (Rome); 2015 Apr; 16(4):193-7. PubMed ID: 25959752
    [No Abstract]   [Full Text] [Related]  

  • 34. Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF.
    Metra M; Ponikowski P; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Hua TA; Severin T; Unemori E; Voors AA; Teerlink JR
    Eur Heart J; 2013 Oct; 34(40):3128-36. PubMed ID: 23999454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and Synthesis of Potent, Long-Acting Lipidated Relaxin-2 Analogs.
    Muppidi A; Lee SJ; Hsu CH; Zou H; Lee C; Pflimlin E; Mahankali M; Yang P; Chao E; Ahmad I; Crameri A; Wang D; Woods A; Shen W
    Bioconjug Chem; 2019 Jan; 30(1):83-89. PubMed ID: 30543420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relaxin for the Treatment of Acute Decompensated Heart Failure: Pharmacology, Mechanisms of Action, and Clinical Evidence.
    Ng TM; Goland S; Elkayam U
    Cardiol Rev; 2016; 24(4):194-204. PubMed ID: 26331289
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant human relaxin-2: (how) can a pregnancy hormone save lives in acute heart failure?
    Dschietzig TB
    Am J Cardiovasc Drugs; 2014 Oct; 14(5):343-55. PubMed ID: 24934696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant human H2 relaxin (serelaxin) as a cardiovascular drug: aiming at the right target.
    Bani D
    Drug Discov Today; 2020 Jul; 25(7):1239-1244. PubMed ID: 32360533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Worsening Heart Failure Following Admission for Acute Heart Failure: A Pooled Analysis of the PROTECT and RELAX-AHF Studies.
    Davison BA; Metra M; Cotter G; Massie BM; Cleland JGF; Dittrich HC; Edwards C; Filippatos G; Givertz MM; Greenberg B; Ponikowski P; Voors AA; O'Connor CM; Teerlink JR;
    JACC Heart Fail; 2015 May; 3(5):395-403. PubMed ID: 25951761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and tolerability of serelaxin, a recombinant human relaxin-2 in development for the treatment of acute heart failure, in healthy Japanese volunteers and a comparison of pharmacokinetics and pharmacodynamics in healthy Japanese and Caucasian populations.
    Dahlke M; Ng D; Yamaguchi M; Machineni S; Berger S; Canadi J; Rajman I; Lloyd P; Pang Y
    J Clin Pharmacol; 2015 Apr; 55(4):415-22. PubMed ID: 25408331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.